Health policy Outrage, confusion caused by potential loss of $600 million for public health By Emily Land, MA
Research New research: High prevention efficacy and “breakthrough infections” on lenacapavir for PrEP By Emily Land, MA
Research New research: Out of thousands, only 42 people started long-acting injectable PrEP By Emily Land, MA
HIV Bictegravir/lenacapavir single-tablet once-daily regimen shows promise for HIV treatment By Emily Land, MA
Community “There’s anxiety, and fear”: How HIV long-term survivors are processing the current political moment By Emily Land, MA
Health policy CDC cuts, millions in NIH grants canceled, layoffs at HHS: Our quick summary of recent news impacting HIV & LGBTQ+ services and health By Emily Land, MA
Research 100% efficacy in HIV prevention for teens taking powerful drug lenacapavir By Emily Land, MA
Sexual health “Substantial and sustained” decline in chlamydia and syphilis among Doxy PEP users in Northern California By Emily Land, MA
Community HIV trends: ‘One-size-fits-all’ fails our communities By Emily Land, MA and San Francisco AIDS Foundation
PrEP Does PrEP work for trans people taking gender-affirming hormones? Yes, says new research By Emily Land, MA
Harm reduction Have questions about bringing safe injection sites to San Francisco? Here’s some key info. By Emily Land, MA
Research “Tremendously exciting” news of cabotegravir long-acting injectable for PrEP shared at AIDS 2020 By Emily Land, MA
